Pancreatic Cancer Breakthrough: New Pill Daraxonrasib Doubles Survival in Advanced Cases

For forty years, scientists have stared at a locked door. The KRAS gene, mutated in more than nine out of every ten pancreatic cancers, seemed impossible to target with drugs. Researchers called it undruggable. Patients died. Doctors ran out of options. Then, in June 2026, researchers presented results from a trial of a once-daily pill called daraxonrasib that may have finally cracked the problem open.

The numbers are stark enough to have stopped a room full of oncologists mid-breath. In the Phase 3 RASolute 302 trial, patients with advanced pancreatic cancer that had already resisted prior treatment lived a median of 13.2 months after taking daraxonrasib. Those given standard second-line chemotherapy lived 6.6 to 6.7 months. Nearly double. The trial enrolled roughly 500 patients with metastatic pancreatic ductal adenocarcinoma—the most common form of the disease—and the results were presented at the 2026 Annual Meeting of the American Society of Clinical Oncology and published simultaneously in the New England Journal of Medicine. The standing ovation that followed was unusual enough that observers noted it. Oncologists called the findings practice-changing, the biggest advance in pancreatic cancer treatment in decades.

Pancreatic cancer has always been among the cruelest of malignancies. Symptoms arrive late—abdominal pain, weight loss, jaundice, digestive trouble—often mistaken for something less serious. By the time diagnosis comes, the disease has usually spread. Survival rates globally remain grim compared to other cancers. Once metastatic, options narrow sharply. For years, the best second-line chemotherapy could offer was measured in months, not years. Patients and their doctors faced a narrowing corridor with few doors.

Daraxonrasib works by targeting the active form of RAS proteins, which fuel tumor growth. The drug belongs to a new class called RAS(ON) inhibitors and operates differently from earlier targeted therapies that focused on specific KRAS subtypes. This one acts as a multiselective inhibitor, capable of hitting a broader range of RAS-driven cancers. Scientists believe this wider reach explains why it worked across multiple mutation types in the trial. It is, in essence, the first tool that actually works against a target that has eluded the field for four decades.

Equally important: the drug appeared gentler than chemotherapy. Side effects were common—rash, diarrhea, nausea, fatigue, vomiting, mouth inflammation—but mostly manageable. Severe treatment-related side effects occurred less often than with chemotherapy, and fewer patients quit treatment because they could not tolerate it. For people already carrying the physical and emotional weight of advanced cancer, this matters. It matters a great deal.

The implications reach beyond pancreatic cancer. RAS mutations drive lung cancer and colorectal cancer too. Scientists believe the success of daraxonrasib could accelerate development of similar therapies across multiple cancer types, finally unlocking a door that has been sealed for generations. India, where pancreatic cancer cases are rising due to aging populations, obesity, diabetes, and tobacco use, could see meaningful impact on outcomes for patients who currently have almost nowhere to turn.

Experts are careful to say this is not a cure. Many patients eventually develop resistance. Longer-term studies are needed to see whether survival gains hold. But the magnitude of improvement in the RASolute 302 trial is unprecedented in this setting. Regulatory approval still awaits. The door is not yet fully open. But for patients facing advanced pancreatic cancer, something has shifted. For the first time in decades, there is something that looks like genuine hope.